Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Programmed Cell Death 1 Ligand 1(PDL1, PD-L1)”

1,546 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 1,546 results

Testing effectiveness (Phase 2)Looking for participantsNCT06662006
What this trial is testing

Nal-IRI/5-FU/LV Chemotherapy Combined With PD-L1 Inhibitor and Multi-target Anti-angiogenic Small Molecule±SBRT as Second-line Therapy in Metastatic Pancreatic Cancer Patients

Who this might be right for
Advanced Metastatic Pancreatic Cancer
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School 56
Testing effectiveness (Phase 2)Looking for participantsNCT07130032
What this trial is testing

Efficacy And Safety Of Anti-PD-1/PD-L1 Antibodies In Combination With Bevacizumab And Metronomic Cyclophosphamide In Patients With Non-Small Cell Lung Cancer And Cutaneous Melanoma Previously Treated With Immune Checkpoint Blockade

Who this might be right for
Metastatic Non-small Cell Lung Cancer (NSCLC)Metastatic Cutaneous Melanoma
EuroCityClinic LLC 90
Large-scale testing (Phase 3)Active Not RecruitingNCT04736706
What this trial is testing

Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)

Who this might be right for
Carcinoma, Renal Cell
Merck Sharp & Dohme LLC 1,854
Not applicableStudy completedNCT03305133
What this trial is testing

Evaluation of PD-L1 (Programmed Death-Ligand 1) Tumor Expression in Patients With Large-cell Neuroendocrine Carcinoma (NEC)

Who this might be right for
Large Cell Lung CancerNeuroendocrine Carcinoma of Lung (Diagnosis)
Groupe Francais De Pneumo-Cancerologie 86
Testing effectiveness (Phase 2)Looking for participantsNCT06780085
What this trial is testing

Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Merck Sharp & Dohme LLC 96
Large-scale testing (Phase 3)Not Yet RecruitingNCT07361484
What this trial is testing

Docetaxel Plus Plinabulin vs Docetaxel Plus Placebo in Advanced/Metastatic Non-Squamous NSCLC After PD-1/PD-L1 Therapy and Platinum Chemotherapy (DUBLIN-4)

Who this might be right for
Non-Small Cell Lung CancerNon-squamous Non-Small Cell Lung Cance
BeyondSpring Pharmaceuticals Inc. 442
Early research (Phase 1)Not Yet RecruitingNCT06743555
What this trial is testing

Surgery After Verifying Existing Disease in Locally Advanced Operable Lung Cancer: A Pilot Study

Who this might be right for
Non-Small Cell Lung CancerImmunotherapyNeoadjuvant Therapy+2 more
Centre hospitalier de l'Université de Montréal (CHUM) 14
Large-scale testing (Phase 3)Looking for participantsNCT05549297
What this trial is testing

Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)

Who this might be right for
Advanced Melanoma
Immunocore Ltd 540
Not applicableNot Yet RecruitingNCT06708650
What this trial is testing

Combination of SFRT, PD-L1 Inhibitor, and Anti-VEGF in Advanced Hepatocellular Carcinoma

Who this might be right for
Hepatocellular CarcinomaRadiotherapyPD-1 Inhibitors
Guiping People's Hospital 50
Testing effectiveness (Phase 2)Looking for participantsNCT06214143
What this trial is testing

A Clinical Study of T3011 in Combination With PD-1/PD-L1 Inhibitors in Subjects With Advanced Solid Tumors

Who this might be right for
Advanced Solid Tumors
Shanghai Pharmaceuticals Holding Co., Ltd 68
Early research (Phase 1)Ended earlyNCT04795713
What this trial is testing

Study of MT-6402 in Subjects With Advanced Solid Cancer That Expresses PD-L1

Who this might be right for
Advanced Solid TumorNon-small Cell Lung CancerSquamous Cell Carcinoma of Head and Neck
Molecular Templates, Inc. 64
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07497074
What this trial is testing

JSKN033 Combination Therapy in Subjects With Advanced Cervical Cancer

Who this might be right for
Cervical Cancer
Jiangsu Alphamab Biopharmaceuticals Co., Ltd 78
Testing effectiveness (Phase 2)Study completedNCT04740307
What this trial is testing

Safety and Efficacy of Coformulated Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib (E7080/MK-7902) in Advanced Hepatocellular Carcinoma (MK-1308A-004)

Who this might be right for
Advanced Hepatocellular Carcinoma
Merck Sharp & Dohme LLC 116
Testing effectiveness (Phase 2)Ended earlyNCT04489940
What this trial is testing

Bintrafusp Alfa in High Mobility Group AT-Hook 2 (HMGA2) Expressing Triple Negative Breast Cancer

Who this might be right for
Triple Negative Breast Neoplasms
EMD Serono Research & Development Institute, Inc. 11
Testing effectiveness (Phase 2)WithdrawnNCT04064190
What this trial is testing

Vactosertib with Durvalumab in Urothelial Carcinoma Failing Checkpoint Inhibition

Who this might be right for
Urothelial Carcinoma RecurrentAdvanced Urothelial Carcinoma
MedPacto, Inc.
Testing effectiveness (Phase 2)Study completedNCT02031458
What this trial is testing

Atezolizumab in Participants With Programmed Death - Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
Hoffmann-La Roche 667
Not applicableUnknownNCT05426317
What this trial is testing

Exploratory Interventional Study of Prognostic Serum Biomarkers of Cancer Progression

Who this might be right for
MelanomaNon Small Cell Lung CancerRenal Cancer
University Hospital, Clermont-Ferrand 100
Large-scale testing (Phase 3)Study completedNCT02366143
What this trial is testing

Atezolizumab in Combination With Carboplatin Plus (+) Paclitaxel With or Without Bevacizumab Compared With Carboplatin+Paclitaxel+Bevacizumab in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Hoffmann-La Roche 1,202
Testing effectiveness (Phase 2)Study completedNCT04247282
What this trial is testing

Anti-PD-L1/TGF-beta Trap (M7824) Alone and in Combination With TriAd Vaccine and N-803 for Resectable Head and Neck Squamous Cell Carcinoma Not Associated With Human Papillomavirus Infection

Who this might be right for
Head and Neck CancerHead and Neck Neoplasms
National Cancer Institute (NCI) 21
Large-scale testing (Phase 3)Study completedNCT03142334
What this trial is testing

Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (MK-3475-564/KEYNOTE-564)

Who this might be right for
Renal Cell Carcinoma
Merck Sharp & Dohme LLC 994
Next Page